Moleculin Biotech Inc. (MBRX)
Symbol Info
Listed Symbol MBRX
Name Moleculin Biotech Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-0.46
Price Info
21 Day Moving Average $1.1033
21 Day EMA $1.126820
50 Day Moving Average $1.1680
50 Day EMA $1.152380
200 Day EMA $1.280910
200 Day Moving Average 1.241560
52 Week High $3.15
52 Week Low $0.78
52 Week Change $-33.529400
Alpha -0.022265
Beta 1.8690
Standard Deviation 0.332558
R2 0.039469
Periods 38
Share Information
10 Day Average Volume 171,637
20 Day Average Volume 216,098
30 Day Average Volume 257,254
50 Day Average Volume 306,042
Outstanding Shares 45,197,048
Float Shares 43,748,689
Percent Float 96.80%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 32
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 272,768
Institute Holdings Percent 10.000000
Institute Sold Previous 3 Months 129,773
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,448,359
Price Change
7 Day Price Change $0.0700001
7 Day Percent Change 6.60%
21 Day Price Change $0.0700001
21 Day Percent Change 6.60%
30 Day Price Change $-0.02
30 Day Percent Change -1.74%
Month To Date Price Change $0.0400
Month To Date Percent 3.67%
90 Day Price Change $0.010000
90 Day Percent Change 0.89%
Quarter To Date $-0.12
Quarter To Date Percent -9.60%
180 Day Price Change $-0.25
180 Day Percent Change -18.12%
200 Day Price Change $-0.35
200 Day Percent Change -23.65%
Year To Date $0.090000
Year To Date Percent 8.65%
Profile
Description Moleculin Biotech Inc is a clinical-stage pharmaceutical company. The firm focus on the development of oncology drug candidates. The drug technologies used by the company are anthracycline, a portfolio of STAT3 inhibitors, and collection of inhibitors of glycolysis.
Details
Issue Type CS
Market Cap $51,072,664
Sec Type EQS
Auditor Grant Thornton LLP
Total Shares Outstanding 45,197,048
CEO Walter V. Klemp
Employees 13
Last Audit UE
Classification
CIK 0001659617
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 5300 Memorial Drive
Suite 950
Houston, TX 77007
Website http://www.moleculin.com
Facisimile +1 817 394-2127
Telephone +1 713 300-5160
Email mbrx@lythampartners.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $35,260,487
Price To Sales -
Price To Free Cash -3.5
PE High Last 5 Years -
Price To Book 2.4
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 2.4
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 2.1
Leverage Ratio 1.4
Quick Ratio 1.9
Long Term Debt To Capital 0.01
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -36.07
Return On Equity -51.94
Return On Capital -51.39
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
MBRX
Moleculin ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.